Evidence map›Paper›PMID 29263771›Full record

ArticleAmerican health & drug benefits2017

The Cost of Hematopoietic Stem-Cell Transplantation in the United States.

Michael S Broder, Tiffany P Quock, Eunice Chang, Sheila R Reddy, Rajni Agarwal-Hashmi, Sally Arai, Kathleen F Villa

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in American health & drug benefits, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 71 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04645667 completednot on this mapstarted 2021, after this paper: background citation

Development of a Population Pharmacokinetic Model to Optimize Tacrolimus Dosing in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplant.

TypeobservationalSponsorUNC Lineberger Comprehensive Cancer CenterRan2021 to 2023Enrolled38ConditionsAcute GVHDArmsTacrolimus
NCT06802406 narecruitingnot on this mapstarted 2025, after this paper: background citation

Nutrition OUtReach In Systems of Healthcare

TypeinterventionalSponsorUniversity of Kansas Medical CenterRan2025 to 2029Enrolled210ConditionsALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Autologous Haemopoietic Stem Cell Transplant, CAR-T Cell Therapy, Food InsecurityArmsFood Bags
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD.Hematology. American Society of Hematology. Education Program · 2025
    Review
  15. Observational
  16. Article
  17. Intervention Development to Promote Medical Adherence After Stem Cell Transplant.Journal of clinical psychology in medical settings · 2025
    Article
  18. Stem cell transplantation cost in Iran.BMC health services research · 2025
    Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Michael S BroderPresident and CEO, Partnership for Health Analytic Research, Beverly Hills, CA.
Tiffany P QuockAssociate Director, Health Economics & Outcomes Research, Jazz Pharmaceuticals, Palo Alto, CA, during this study.
Eunice ChangChief Statistician, Partnership for Health Analytic Research.
Sheila R ReddyDirector, Health Services Research, Partnership for Health Analytic Research.
Rajni Agarwal-HashmiAssociate Professor, Pediatrics (Stem Cell Transplantation), Stanford University School of Medicine, Palo Alto, CA.
Sally AraiAssociate Professor, Medicine (Blood and Marrow Transplantation), Stanford University School of Medicine.
Kathleen F VillaExecutive Director, Health Economics & Outcomes Research, Jazz Pharmaceuticals.
Partnership for Health Analytic Research · USJazz Pharmaceuticals (Italy) · ITJazz Pharmaceuticals (United States) · USPalo Alto University · USStanford Blood Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHematopoietic stem-cell transplantation (HSCT) requires highly specialized, resource-intensive care. Myeloablative conditioning regimens used before HSCT generally require inpatient stays and are more intensive than other preparative regimens, and may therefore be more costly.

objectiveTo estimate the costs associated with inpatient HSCT according to the type of the conditioning regimen used and other potential contributors to the overall cost of the procedure.

methodWe used data from the Truven Health MarketScan insurance claims database to analyze healthcare costs for pediatric (age <18 years) and adult (age ≥18 years) patients who had autologous or allogeneic inpatient HSCT between January 1, 2010, and September 23, 2013. We developed an algorithm to determine whether conditioning regimens were myeloablative or nonmyeloablative/reduced intensity.

resultsWe identified a sample of 1562 patients who had inpatient HSCT during the study period for whom the transplant type and the conditioning regimen were determinable: 398 patients had myeloablative allogeneic HSCT; 195 patients had nonmyeloablative/reduced-intensity allogeneic HSCT; and 969 patients had myeloablative autologous HSCT. The median total healthcare cost at 100 days was $289,283 for the myeloablative allogeneic regimen cohort compared with $253,467 for the nonmyeloablative/reduced-intensity allogeneic regimen cohort, and $140,792 for the myeloablative autologous regimen cohort. The mean hospital length of stay for the index (first claim of) HSCT was 35.6 days in the myeloablative allogeneic regimen cohort, 26.6 days in the nonmyeloablative/reduced-intensity allogeneic cohort, and 21.8 days in the myeloablative autologous regimen cohort.

conclusionAllogeneic HSCT was more expensive than autologous HSCT, regardless of the regimen used. Myeloablative conditioning regimens led to higher overall costs than nonmyeloablative/reduced-intensity regimens in the allogeneic HSCT cohort, indicating a greater cost burden associated with inpatient services for higher-intensity preparative conditioning regimens. Pediatric patients had higher costs than adult patients. Future research should involve validating the algorithm for identifying conditioning regimens using clinical data.

Indexed as

allogeneic HSCTautologous HSCThealthcare costshospitalizationinpatientmyeloablative conditioning regimennonmyeloablative/reduced-intensity conditioning regimen

Identifiers

PMID29263771
PMCPMC5726064
OpenAlexW3024884870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.